AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 92 min read

Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact

Alumis presented Phase III trial results showing its psoriasis drug, envudeucitinib, achieved significant efficacy and safety milestones. The company plans to submit an NDA in Q4 2026, aiming to compete with Bristol Myers Squibb's Sotyktu, which had $291m in 2023 sales.

Original reporting
finance.yahoo.com
Published Oct 9, 2026, 5:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 5:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

Med
01

Why it matters

Positive efficacy and safety data could drive investor optimism ahead of an NDA filing later this year.

02

Market read

First report of pivotal trial data; may affect biotech sector sentiment and competitor valuations.

03

What to watch

Competitive landscape with BMS's Sotyktu and upcoming FDA review timelines.

Relevance 9/10Novelty 9/10Timing: upon data release

Background

Alumis, a California‑based biopharma, released Phase III trial results for its TYK2 inhibitor envudeucitinib in psoriasis.

Market effects

Sector

Phase III psoriasis data may boost the broader TYK2 inhibitor and oral psoriasis market.

Regional

Limited to U.S. biotech investors; no immediate regional effect.

Global

Potential interest from global dermatology drug developers.

Counterpoint

What could challenge this read

If the data fails to translate into regulatory approval, the hype could fade quickly.

Key entities

  • company
    Alumis

    Biopharma developing envudeucitinib for psoriasis.

  • company
    Bristol Myers Squibb

    Competitor with Sotyktu, a TYK2 inhibitor.

Read at source← All news

StoryAlumis reports Phase 3 envudeucitinib data showing high skin‑clearance and itch relief, NDA slated for Q4 2026

Also covered by

1 outlet

Related articles

OCT 9
$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

mugglehead.com2 min
OCT 9
$ALMSMedAI 8/10

Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up

Alumis Inc. (ALMS) reported Phase 3 data showing envudeucitinib improved scalp psoriasis, itching, and quality of life in patients. Key findings: 54% achieved complete skin clearance, 80% maintained clear scalp skin, and 40% reported complete itch resolution. The drug was well tolerated. ALMS stock rose 2.95% on Thursday and is up 4.02% in premarket trading.

rttnews.com1 min
OCT 9
$ALMSHighAI 9/10

Alumis Reports Positive Phase 3 Data With Envudeucitinib

Alumis (ALMS) reported Phase 3 data for envudeucitinib, showing a 54% PASI 100 response rate at Week 48. The company aims for a 2026 NDA submission. Shares rose 3.49% in pre-market trading to $7.21. According to the CEO, the results support its potential as a leading oral therapy for plaque psoriasis.

rttnews.com1 min